Advances in the management of osteosarcoma
- PMID: 27990273
- PMCID: PMC5130082
- DOI: 10.12688/f1000research.9465.1
Advances in the management of osteosarcoma
Abstract
Osteosarcoma, a bone cancer most commonly seen in adolescents and young adults, is usually a high-grade malignancy characterized by a very high risk for the development of pulmonary metastases. High-grade osteosarcomas are usually treated by preoperative and postoperative chemotherapy and surgery, with a very limited number of active agents available. Rarer lower-grade variants such as parosteal and periosteal osteosarcoma or low-grade central osteosarcoma are treated by surgery only. Imaging to search for possible metastases focuses on the lung. Computed tomography is the most sensitive method but cannot reliably distinguish small metastases from benign lesions. Advances of local imaging and surgical reconstruction now allow the use of limb-salvage in an ever-increasing proportion of patients. While still troubled by complications, non-invasive endoprosthesis-lengthening mechanisms have led to an increased uptake of limb-salvage, even for young, skeletally immature patients. Radiotherapy is employed when osteosarcomas cannot be removed with clear margins, but very high doses are required, and both proton and carbon-ion radiotherapy are under investigation. Unfortunately, the past 30 years have witnessed few, if any, survival improvements. Novel agents have not led to universally accepted changes of treatment standards. In patients with operable high-grade osteosarcomas, the extent of histological response to preoperative chemotherapy is a significant predictive factor for both local and systemic control. Attempts to improve prognosis by adapting postoperative treatment to response, recently tested in a randomized, prospective setting by the European and American Osteosarcoma Study Group, have not been proven to be beneficial. Many agree that only increased knowledge about osteosarcoma biology will lead to novel, effective treatment approaches and will be able to move the field forward.
Keywords: chemotherapy; imaging; osteosarcoma; radiotherapy; surgery.
Conflict of interest statement
Stefan Bielack reports consultancy or advisory board participation for Bayer, Celgene, Clinigen, Chugai, Isofol, Lilly, Merck & Co., Novartis, Pfizer, Roche, and Takeda Millennium. Leo Kager reports advisory board participation for Takeda and travel expenses for Novartis. The other authors declare that they have no competing interests. No competing interests were disclosed. No competing interests were disclosed.
Similar articles
-
Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases.J Clin Oncol. 1994 Sep;12(9):1849-58. doi: 10.1200/JCO.1994.12.9.1849. J Clin Oncol. 1994. PMID: 8083708 Clinical Trial.
-
Osteosarcoma: review of the past, impact on the future. The American experience.Cancer Treat Res. 2009;152:239-62. doi: 10.1007/978-1-4419-0284-9_12. Cancer Treat Res. 2009. PMID: 20213394 Review.
-
[Low grade parosteal osteosarcoma. Clinical and oncological outcomes].Medicina (B Aires). 2015;75(5):303-6. Medicina (B Aires). 2015. PMID: 26502465 Spanish.
-
Non-randomized therapy trial to determine the safety and efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma.BMC Cancer. 2010 Mar 12;10:96. doi: 10.1186/1471-2407-10-96. BMC Cancer. 2010. PMID: 20226028 Free PMC article. Clinical Trial.
-
Current combined treatment of high-grade osteosarcomas.Oncology (Williston Park). 1995 Apr;9(4):327-43; discussion 343-4, 347-50. Oncology (Williston Park). 1995. PMID: 7547198 Review.
Cited by
-
Integrated immunogenomic analyses of single-cell and bulk profiling construct a T cell-related signature for predicting prognosis and treatment response in osteosarcoma.Discov Oncol. 2024 Oct 22;15(1):579. doi: 10.1007/s12672-024-01461-8. Discov Oncol. 2024. PMID: 39436466
-
The EphA2 Receptor Regulates Invasiveness and Drug Sensitivity in Canine and Human Osteosarcoma Cells.Cells. 2024 Jul 16;13(14):1201. doi: 10.3390/cells13141201. Cells. 2024. PMID: 39056783 Free PMC article.
-
Comparative responses to demethylating therapy in animal models of osteosarcoma.Res Sq [Preprint]. 2024 Jun 11:rs.3.rs-4451060. doi: 10.21203/rs.3.rs-4451060/v1. Res Sq. 2024. PMID: 38946977 Free PMC article. Preprint.
-
WNT5B drives osteosarcoma stemness, chemoresistance and metastasis.Clin Transl Med. 2024 May;14(5):e1670. doi: 10.1002/ctm2.1670. Clin Transl Med. 2024. PMID: 38689429 Free PMC article.
-
Prognostic Nomogram of Osteocarcinoma after Surgical Treatment.J Oncol. 2022 Sep 21;2022:9778555. doi: 10.1155/2022/9778555. eCollection 2022. J Oncol. 2022. PMID: 37954859 Free PMC article.
References
-
- Odes EJ, Randolph-Quinney PS, Steyn M, et al. : Earliest hominin cancer: 1.7-million-year-old osteosarcoma from Swartkrans Cave, South Africa. S Afr J Sci. 2016;112:5 10.17159/sajs.2016/20150471 - DOI
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
